ClinicalTrials.gg
Status unknownNCT01558466SildenoUpdated Sep 25, 2012

Sildenofil in Persistent Pulmonary Hypertension in Newborns

A Phase 3 interventional study of Sildenafil and diluent in Persistent Fetal Circulation Syndrome, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 36 Weeks to 41 Weeks. Per ClinicalTrials.gov, last updated 2012-09-25.

Sponsored by Hamad Medical Corporation · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
36 Weeks to 41 Weeks
Sex
All
01

Study summary

This study hopes to evaluate the effectiveness of early combined use of Sildenafil and nitric oxide (iNO) in newborns with Persistent pulmonary hypertension (PPHN) and or hypoxemic respiratory failure and assess whether this would improve oxygenation, improve time on mechanical ventilation for these babies and also prevent rebound hypoxic episodes.

Read the detailed description

PPHN is characterized by hyper reactivity of the muscle layer in pulmonary arterioles and right to left shunt across the ductus arteriosus and the foramen ovale in the absence of structural heart defects. It could also include right ventricle dysfunction in many cases. The reported incidence of this disease is 0.43 to 6.8/1000 live new born infants with a mortality of 10-20%.

The main objective of therapy in PPHN is to reduce pulmonary vascular resistance. To this purpose, inhaled nitric oxide has been used in developed and several under developed countries. However 30-40% of these patients do not respond to this therapy. Extra corporeal membrane oxygenation is also useful but is an invasive therapy in PPHN with serious adverse effects reported. Recently Sildenafil has been evaluated as an alternative or adjunctive pulmonary vasodilator. It inhibits phosphodiesterase type 5 and elevates the concentration of cyclic guanosine monophosphate in the muscle cells of pulmonary vessels, which in turn decreases pulmonary vascular resistance.

The FDA in the USA has recently approved the use of Sildenafil for use in adults with PPHN.

Recently 3 clinical trials have evaluated Sildenafil versus Placebo or control in newborns with PPHN,all of them showing a significant improvement in oxygenation index, decreased mortality and reduced risk of rebounds after discontinuing iNO. The use of Sildenafil in treating PPHN secondary to Chronic lung disease in older infants had been receiving significant attention over the last few years.

At HMC, Women's hospital, the number of deliveries average 15,000 to 16,000 per year with an admission rate to the NICU of about 10%. The number of PPHN cases admitted to our NICU ranges between 14-20 cases per year.

In this study the investigators plan to compare the effectiveness of the use of early combined Sildenafil and iNO in newborns with PPHN and or hypoxemic respiratory failure and whether it would improve oxygenation, decrease the time spent in mechanical ventilation and prevent rebound hypoxic episodes.

02

Conditions studied

  • Persistent Fetal Circulation Syndrome

Keywords

  • newborn
  • INO
  • Sildenafil
  • PPHN
03

In context

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

This study's planned enrollment of 100 is above the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.

Browse Persistent Fetal Circulation Syndrome studies →

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
36 Weeks to 41 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newborn infants of post natal age less than 48 hours
  2. Gestational age equal to or more than 34 weeks
  3. Oxygen index of more than or equal to 20 (moderately ill infants)
  4. Radiological, clinical and biochemical evidence of acute hypoxic respiratory failure
  5. Surfactant therapy has been established when indicated
  6. Presence of arterial line

Exclusion criteria

Exclusion Criteria:

  1. Congenital diaphragmatic hernia
  2. Major congenital abnormalities
  3. Significant congenital heart disease
  4. Cyanotic congenital heart disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Group A - Placebo

    iNO combined with placebo will be administered

    Drug: diluent

  • Active comparator
    Group B- Sildenafil

    iNO combined with Sildenafil

    Drug: Sildenafil

Interventions

  • 50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.

    Also known as: Viagra

  • Drugdiluent

    The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Oxygen index

    OI= PaO2 X FiO2/100( Absolute values and change from baseline measurement after first dose, measured every 6 hours for 7 days while on therapy. Improvement in OI is defined as decrease in OI of 20% from the previously calculated value.

    Time frame: 7 days after birth and admission to the NICU

  2. A-a gradient

    Alveolar arterial oxygen difference gradient

    Time frame: 7 days after admission to the NICU

  3. Hemodynamic parameters

    Hemodynamic parameters ( absolute values and change from baseline measured after the first dose, after 24 hours, after 36 hours, and after 48 hours and every 12 hours thereafter for a total of 7 days while receiving therapy and 7 days after the end of treatment including : 1. Heart rate, mean blood pressure, respiratory rate, oxygen saturation and blood gas b. Pulmonary arterial pressure in mm Hg measured by echocardiography c. cArdiac output in liter/kg/min d. Oxygenation ( PaO2) and FiO2 requirement

    Time frame: 7 days

Secondary outcomes

  1. Days of hospitalization

    Length of hospitalization and mortality, morbidity, ventialtion dats , adverse events

    Time frame: 7 days after admission to the NICU

  2. mortality

    All cause mortality within 28 days of life

    Time frame: 28 days of life

07

Study locations

1 of 1 sites recruiting
  • Women's hospital, NICU
    Doha, 00974, Qatar
    Recruiting
    • Husam Salama, MD · Contacthsalama1@hmc.org.qa · 552262159
    • Ahmad Masoud, MD · Contactamasoud@hmc.org.qa · 55112369
    • Husam Salama, MD · Principal investigator
    • Ahmad Masoud, MD · Principal investigator
    • Moza Al Hail, BpH · Sub investigator
    • Hilal Al Rifai, MD · Sub investigator
    • Mohamed Bunaiha, BpH · Sub investigator
    • Samawal Lutfi, MD · Sub investigator
    • Mohamad Delawar, MD · Sub investigator
    • Badr Kurdi, MD · Sub investigator
    • Afif Ali, B.PH · Sub investigator
    • Robert Hightree, RT · Sub investigator
    • Ghassan Abdoh, MD · Sub investigator
    • Samer Taha, Fellowship · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2012
First posted
Mar 20, 2012
Start
Nov 2011
Primary completionEst.
Nov 2014
CompletionEst.
Jun 2015
Last update
Sep 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01558466
Responsible party
Sponsor
First posted
Mar 20, 2012
Start date
Nov 2011
Primary completion
Nov 2014 (estimated)
Completion
Jun 2015 (estimated)
Last update
Sep 25, 2012

Study contacts

Husam Em Salama, MRCP
Contact
hsalama1@hmc.org.qa
00974- 55262159
Ahmed Masoud, MD
Contact
amasoud@hmc.org.qa
00974-55112369
Husam Salama, MD
principal investigator · Hamad Medical Corporation, Doha, Qatar

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion